Sign Up Today and Learn More About Arvinas Stock
Invest in or calculate the value of your shares in Arvinas or other pre-IPO companies through EquityZen's platform.
Arvinas Stock
Arvinas is a pharmaceutical company focused on protein degradation approaches to develop novel drugs to treat cancer and other diseases.
About Arvinas Stock
Founded
2013
Headquarters
New Haven, CT, US
Total Funding
112M
Industries
Messaging and Telecommunications, Content and Publishing, Sports
Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. This strategy of degradation versus protein inhibition holds several advantages including the potential to target proteins that are not currently ‘druggable’ using a small molecule approach.
Arvinas Press Mentions
Stay in the know about the latest news on Arvinas
New Haven's Arvinas Raises $55M To Begin Cancer Trials
Hartford Courant • Apr 04, 2018
Yale startup partners with big pharma
Yale Daily News (blog) • Jan 25, 2018
Arvinas to expand at Science Park, add 30 jobs
• Jan 19, 2018
Pfizer and Arvinas sign $830M drug development deal that target proteins causing disease
MedCity News • Jan 04, 2018
Genentech inks $650M deal with protein degradation pioneer Arvinas
Endpoints News • Nov 15, 2017
Arvinas Management
Leadership team at Arvinas
CEO
Timothy Shannon
Founder
Craig M. Crew
Join now and verify your accreditation status to gain access to:
- Arvinas Current Valuation
- Arvinas Stock Price
- Arvinas Management
- Available deals in Arvinas and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Arvinas Cap Table and Funding History by Share Class and Liquidity Preferences
- Arvinas Revenue and Financials
- Arvinas Highlights
- Arvinas Business Model
- Arvinas Risk Factors
- Arvinas Research Report from SACRA Research
Trading Arvinas Stock
How to invest in Arvinas stock?
Accredited investors can buy pre-IPO stock in companies like Arvinas through EquityZen funds. These investments are made available by existing Arvinas shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Arvinas stock?
Shareholders can sell their Arvinas stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."